MiMedx Group

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiMedx Group reports robust Q4 performance and eyes growth opportunities

MiMedx Group's Q4 2022 earnings call highlighted strong performance, strategic focus on growth objectives, and addressing challenges in reimbursement and regulatory landscape. The company's emphasis on technology, personnel, and growth opportunities positions it for continued success.

MiMedx Group reports robust Q1 performance and eyes international growth

MiMedx Group's Q1 2023 performance reflects a balanced focus on profitability and revenue growth, driven by new product launches and strategic initiatives.
Despite challenges such as product launch delays and market dynamics, the company remains optimistic about growth opportunities in Japan and beyond.
With a strong emphasis on efficiency, innovation, and market expansion, MiMedx Group is positioned for continued growth and success in the evolving healthcare landscape.

MiMedx Group excels in Q2, eyes growth amid challenges

MiMedx Group's Q2 2023 performance reflects strong financial results, operational efficiency, and a strategic shift towards wound and surgical markets.
While facing challenges related to supply chain disruptions and regulatory compliance, the company is well-positioned to capitalize on growth opportunities and drive innovation.
Investors can be optimistic about MiMedx Group's financial outlook, legal standing, and commitment to market expansion through product development and strategic partnerships.

MiMedx Group reports robust Q3 earnings, eyes Japanese market growth

MiMedx Group's Q3 performance reflects strong financial results, strategic product launches, and growth in key markets despite challenges.
The company's focus on operational efficiency, expansion in the Japanese market, and product portfolio diversification position it well for future success.
While facing challenges from Medicare LCD changes and potential cannibalization, MiMedx remains optimistic about growth opportunities and aims for continued momentum.

MiMedx Group excels in Q4, poised for sustained growth

MiMedx Group's Q4 performance exceeded expectations with revenue growth and improved margins.
The company's strategic focus on growth drivers and financial discipline sets a strong foundation for 2024.
While facing challenges in certain areas, MiMedx is well-positioned to capitalize on opportunities for expansion.
Overall, MiMedx's financial health and growth prospects indicate a positive outlook for the future.

MiMedx Group reports robust Q1 earnings amidst strategic growth plans

MiMedx Group (MDXG) had a strong start in Q1 2024, showcasing financial strength and strategic focus on growth.
The company faces challenges from potential market disruptions and cost pressures but remains optimistic about opportunities.
Key initiatives include product innovation, market expansion, and navigating reimbursement landscape changes.

MiMedx Group reports solid Q2 earnings, navigates reimbursement challenges

MiMedx Group's Q2 performance reflects steady growth, strong financial health, and a strategic focus on innovation and customer relationships.
While facing challenges in reimbursement dynamics and regulatory uncertainties, the company remains resilient and poised for growth opportunities in the market.
With a solid product portfolio and emphasis on operational efficiency, MiMedx Group is well-positioned to navigate challenges and capitalize on future market prospects.

MiMedx Group reports solid Q3 growth amid reimbursement challenges

MiMedx Group's Q3 performance reflects resilience and growth amidst challenges, with a focus on innovation and customer-centric strategies for future success.
The company's financial stability, positive market reception of HELIOGEN, and increasing platform adoption position it well for capitalizing on opportunities ahead.
While facing challenges in reimbursement dynamics and operational efficiency, MiMedx Group remains optimistic about future corrections and growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Funding Enables Evaluation of PURION® Processed Placental Tissue as an Innovative Approach in the Management of Acute Military-Related Injuries, Addressing a Critical Unmet Need

MIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns

Follows Previous Recommendation from Glass Lewis in Support of ALL Proposals

Leading Independent Proxy Advisory Firm ISS Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company's Proposals

Recommends Shareholders Vote “FOR” Both of MIMEDX's Highly Qualified Director Nominees – James L. Bierman and Phyllis Gardner, M.D.

Leading Independent Proxy Advisory Firm Glass Lewis Recommends that MIMEDX Shareholders Vote “FOR ALL” of the Company's Proposals

Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have  Established Strong, New Foundation for Growth

MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation

Disappointed that the MiMedx Board Has Resorted to Disinformation and Distortions to Distract Shareholders from the Board's and Management's Own Failures Reiterates Intention to Withhold Votes Against Directors Phyllis Gardner and James Bierman at 2022 Annual Meeting and Vote Against Approval of Executive Compensation BATON ROUGE, La. , May 18, 2022 /PRNewswire/ --  Prescience Point Capital Management LLC ("Prescience Point"), a research-focused, catalyst-driven investment firm that beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group, Inc. ("MDXG" or the "Company") (NASDAQ: MDXG), today issued the following statement: "In recent press releases and letters, MiMedx has misleadingly portrayed Prescience Point as a lone disgruntled shareholder.

Prescience Point Capital Management Calls on MiMedx to Confirm the Company Has Received Letters of Serious Concern from other Shareholders

Intends on Withholding Votes Against Directors Phyllis Gardner and James Bierman at 2022 Annual Meeting and Vote Against Approval of Executive Compensation BATON ROUGE, La. , May 6, 2022 /PRNewswire/ -- Prescience Point Capital Management LLC ("Prescience Point"), a research-focused, catalyst-driven investment firm that beneficially owns approximately 6.7% of the outstanding common stock of MiMedx Group, Inc. ("MDXG" or the "Company") (NASDAQ: MDXG), today issued an open letter to shareholders announcing its intent to WITHHOLD its votes against two members of MDXG's Board of Directors, Phyllis Gardner and James Bierman, who are up for election at the Company's annual meeting of shareholders on June 7, 2022.

Prescience Point Capital Management Issues Open Letter to Shareholders of MiMedx Group

MARIETTA, Ga., May 05, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will participate in the following investor conferences:

MIMEDX to Participate at Upcoming Investor Conferences

MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Jack Howarth - Senior Vice President, Investor Relations Tim Wright - Chief Executive Officer Pete Carlson - Chief Financial Officer Rohit Kashyap - Executive Vice President and Chief Commercial Officer Robert Stein - Executive Vice President, Research and Development Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets John Vandermosten - Zacks SCR Operator Ladies and gentlemen, thank you for standing by.

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q1 2022 Results - Earnings Call Transcript

First Quarter Net Sales of $58.9 Million Reflects Double-Digit Revenue Increase for the Third Straight Quarter in the Company's Continuing Portfolio of Products

MIMEDX Announces First Quarter 2022 Operating and Financial Results

Shareholders Urged to Support MIMEDX Board

MIMEDX Comments on Prescience Point's Recent Filing

MARIETTA, Ga., April 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the first quarter ended March 31, 2022 after the market close on Tuesday, May 3, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results on Wednesday, May 4, 2022, beginning at 8:30 a.m. Eastern Time.

MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4

Company to Sponsor Symposium and Present Three Poster Abstracts

MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring

TAMPA, Fla. , March 16, 2022 /PRNewswire/ -- Leading wound care management and clinical services provider, WoundGenex, today announced a strategic partnership with MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX"), a transformational placental biologics company, to launch an exclusive version of WoundGenex's Premier Graft Program to its clients across the country, providing clinicians access to industry-leading allograft products through a convenient purchasing option.

WoundGenex Partners with MIMEDX to Launch Premier Graft Program to Wound Care Providers Nationwide

MARIETTA, Ga., March 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the Canaccord Genuity Musculoskeletal Conference in Chicago on Tuesday, March 22 at 10:30 AM CDT / 11:30 AM EDT. Institutional investors interested in a meeting with management during the conference may reach out to their Canaccord Genuity representative.

MIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q4 2021 Results - Earnings Call Transcript

Fourth Quarter Net Sales of $67.4 M illion and Full Year 2021 Net Sales of $258.6 M illion; Reflects a Double-Digit Revenue Increase in the Company's Continuing Portfolio of Products

MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Use of MIMEDX PURION® Processed DHACM Provided Improved Clinical Benefits, Shorter Average Length of Treatment and Increased Quality-Adjusted Life Years

Peer-Reviewed Study Demonstrates Increased Cost-Effectiveness of MIMEDX Dehydrated Human Amnion Chorion Membrane (DHACM) in Lower Extremity Diabetic Ulcer (LEDU) Treatment Compared to Standard of Care

MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the fourth quarter ended December 31, 2021 after the market close on Monday, February 28, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.

MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28

MARIETTA, Ga., Jan. 28, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that a federal court in Georgia has denied a motion to reconsider the dismissal of Carpenters Pension Fund of Illinois' (“CPFI”) putative class action lawsuit claiming that the Company violated the federal securities laws.

MIMEDX Announces Dismissal of Putative Securities Class Action Lawsuit

MARIETTA, Ga., Jan. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference

Company to Share Probability Values from its Knee Osteoarthritis (KOA) Study; Analyses Conducted Support Confidence in Initiation of Confirmatory Phase 3 Trials in 2022

MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day

MARIETTA, Ga., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 to December 2, 2021.

MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference

MIMEDX PURION® Processed Placental Allografts Proved Safer Than Autologous Tissue, Reducing Infection, Scarring and Reoperation Rates

Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM) Outperforms Standard of Care in Select Mohs Defect Reconstructions

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2021 Results - Earnings Call Transcript

Third Quarter Net Sales of $63.1 Million Versus $64.3 Million in 3Q20

News for MiMedx Group Stock (MDXG)